Understanding Elacestrant Prescribing Information: A Comprehensive Guide for Medical Professionals
Elacestrant is a novel therapeutic agent that has been developed for the management of estrogen receptor-positive (ER+) breast cancer. Its unique mode of action and promising clinical trial results have generated a lot of interest in the medical community.
As a medical professional, it is important to have a clear understanding of the prescribing information for elacestrant so that you can make informed decisions about its use in your patients. In this article, we will provide you with a comprehensive guide to elacestrant prescribing information.
Introduction
Elacestrant is an oral selective estrogen receptor degrader (SERD) that has been designed to target ER+ breast cancer, which accounts for about 70% of all breast cancer cases. Unlike other endocrine therapies, such as tamoxifen or aromatase inhibitors, elacestrant binds to the estrogen receptor and causes its degradation.
The unique mechanism of action of elacestrant has shown to be effective in preclinical and clinical studies. In fact, a phase II trial demonstrated that elacestrant was able to induce tumor shrinkage in over 40% of patients with ER+ metastatic breast cancer.
Elacestrant Prescribing Information
Elacestrant is indicated for the treatment of postmenopausal women with ER+, HER2-negative (HER-) advanced or metastatic breast cancer who have disease progression on or after endocrine therapy. The recommended dose is 400 mg once daily, taken orally.
Elacestrant is contraindicated in patients with severe hepatic impairment and in patients who are taking strong CYP3A inhibitors. It may also interact with other medications, such as proton pump inhibitors and antacids.
Patients should be monitored closely for adverse reactions, such as hot flashes, fatigue, and nausea. Elacestrant may also cause changes in laboratory results, such as increased levels of liver enzymes or cholesterol.
Conclusion
Elacestrant is a promising therapy for the management of ER+, HER- advanced or metastatic breast cancer. Its unique mechanism of action and promising clinical trial results make it an attractive option for medical professionals to consider for their patients.
As with any medication, it is important to understand the elacestrant prescribing information so that you can make informed decisions about its use in your patients. By staying up-to-date on the latest information about elacestrant, you can provide your patients with the best possible care.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)
Speech tips:
Please note that any statements involving politics will not be approved.